Drug Database
Back to search

Poland· PL-100460464

Trodelvy

A sacituzumab govitecan product containing sacituzumabum govitecanum, registered in Poland by Gilead Sciences Ireland UC. The same ATC class is registered in 14 of our 19 countries.

ATC L01FX17

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedTrodelvyATCL01FX17REGISTER NO.PL-100460464PACKS LISTED2CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about sacituzumabum govitecanumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Sacituzumab govitecan is registered in 14 of 19 countries.

Countries holding a registration under ATC L01FX17 (sacituzumab govitecan), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 9 of them publish a price we can compare per daily dose
Search sacituzumab govitecan products by name

Sacituzumab govitecan · ATC L01FX17

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of sacituzumab govitecan costs, country by country.

Normalised to the WHO defined daily dose (67 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Sacituzumab govitecan · price per daily dose (67 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$458.52
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Sacituzumabum govitecanum
Manufacturer
Gilead Sciences Ireland UC
Country
Poland (PL)
ATC code
L01FX17
ATC class
Sacituzumab govitecan
Defined daily dose
67 mg, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    05391507146816
  • gtin
    05391507146939

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

60 interactions on record for sacituzumab govitecan.

Graded by severity as the source publishes them — 36 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check sacituzumab govitecan against other medicinesHow interaction checks work

Sacituzumab govitecan · interactions on record

60 records

  • 36 severe
  • 24 moderate

Most severe, free to view

  • FostamatinibB02BX09severe
  • CladribineL01BB04severe
  • IrinotecanL01CE02severe
  • NilotinibL01EA03severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Sacituzumab govitecan in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All sacituzumab govitecan products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Trodelvy
  • Liechtenstein · Trodelvy
  • Norway · Trodelvy

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f7d79ae5-8e4a-4dc3-9cdb-c6f68c74e1f1
GET /v1/drugs/f7d79ae5-8e4a-4dc3-9cdb-c6f68c74e1f1?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Proszek do sporządzania koncentratu roztworu do infuzji",
  "source": "urpl",
  "strength": "200 mg",
  "packaging": "05391507146816 ¦ Rpz ¦ EU/1/21/1592/001 ¦ 142507\n1 fiol. 200 mg proszku\n¦ UR/Z/4c/041/22 - 05391507146939 ¦ UR/Z/4c/045/22 - 05391507146939",
  "substance": "Sacituzumabum govitecanum 200 mg",
  "common_name": "Sacituzumabum govitecanum",
  "pl_product_id": "100460464",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about sacituzumab govitecan.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console